Zobrazeno 1 - 10
of 2 486
pro vyhledávání: ''
Autor:
Masayuki Takeda, Tomohide Tamura, Kohei Akiyoshi, Masahiro Morise, Naofumi Shinagawa, Toshiaki Saeki, Naoki Inui, Morihito Okada, Shunichi Sugawara, Kaoru Kubota, Yasutaka Watanabe, Akito Hata, Isamu Okamoto
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(2)
PURPOSE We evaluated the efficacy and safety of fosnetupitant (FosNTP) versus fosaprepitant (FosAPR) for preventing highly emetogenic chemotherapy-induced nausea and vomiting. This phase III study was the first head-to-head comparison between two dif
Autor:
Christopher J. Patterson, Lian Xu, Tanya Siddiqi, Maria Luisa Guerrera, Shayna Sarosiek, Zachary R. Hunter, Andrew R. Branagan, Xia Liu, Carly Leventoff, Catherine A Flynn, Ranjana H. Advani, Kirsten Meid, Nicholas Tsakmaklis, Maria Demos, Matthew S. Davids, Guang Yang, Amanda Kofides, Timothy P White, Manit Munshi, Steven P. Treon, Jorge J. Castillo, Richard R. Furman, John N. Allan
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(1)
PURPOSE BCL2 is overexpressed and confers prosurvival signaling in malignant lymphoplasmacytic cells in Waldenström macroglobulinemia (WM). Venetoclax is a potent BCL2 antagonist and triggers in vitro apoptosis of WM cells. The activity of venetocla
Autor:
Bradley R. Pieters, Fernanda G. Herrera, Antoine Engelen, Philippe Maingon, Santhanam Sundar, Christopher D Scrase, John Armstrong, Alphonsus C. M. van den Bergh, Ana Boladeras, Elzbieta van der Steen-Banasik, Michel Bolla, Amit Bahl, Laurence Collette, Christian Carrie, Joe M O'Sullivan, Demetrios Andreopoulos, Jihane Boustani, Annerie Slot, Anouk Neven, Jan Jansa, David Azria, Karine Peignaux-Casasnovas
Publikováno v:
Journal of clinical oncology, vol. 39, no. 27, pp. 3022-3033
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(27), 3022-3033. AMER SOC CLINICAL ONCOLOGY
Journal of clinical oncology, 39(27), 3022-3033. American Society of Clinical Oncology
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(27), 3022-3033. AMER SOC CLINICAL ONCOLOGY
Journal of clinical oncology, 39(27), 3022-3033. American Society of Clinical Oncology
PURPOSE The European Organisation for Research and Treatment of Cancer (EORTC) trial 22991 ( NCT00021450 ) showed that 6 months of concomitant and adjuvant androgen suppression (AS) improves event- (EFS, Phoenix) and clinical disease-free survival (D
Autor:
Hervé Tilly, Gilles Salles, Wolfram Klapper, Stephan Stilgenbauer, Martin Dreyling, Christian Schmidt, Michael Unterhalt, Pierre Feugier, Eva Hoster, Christiane Pott, Josée M. Zijlstra, Lothar Kanz, Jan Walewski, Vincent Ribrag, Michal Szymczyk, Jeanette K. Doorduijn, Olivier Hermine, Marek Trneny, Christian H. Geisler, Florian Kaiser, Hanneke C. Kluin-Nelemans, Catherine Thieblemont
Publikováno v:
Journal of Clinical Oncology, 38(3), 248-256. AMER SOC CLINICAL ONCOLOGY
Journal of Clinical Oncology, 38(3), 248-+. American Society of Clinical Oncology
Kluin-Nelemans, H C, Hoster, E, Hermine, O, Walewski, J, Geisler, C H, Trneny, M, Stilgenbauer, S, Kaiser, F, Doorduijn, J K, Salles, G, Szymczyk, M, Tilly, H, Kanz, L, Schmidt, C, Feugier, P, Thieblemont, C, Zijlstra, J M, Ribrag, V, Klapper, W, Pott, C, Unterhalt, M & Dreyling, M H 2020, ' Treatment of Older Patients With Mantle Cell Lymphoma (MCL) : Long-Term Follow-Up of the Randomized European MCL Elderly Trial ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, no. 3, pp. 248-256 . https://doi.org/10.1200/JCO.19.01294
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(3), 248-256. American Society of Clinical Oncology
Journal of Clinical Oncology, 38(3), 248-+. American Society of Clinical Oncology
Kluin-Nelemans, H C, Hoster, E, Hermine, O, Walewski, J, Geisler, C H, Trneny, M, Stilgenbauer, S, Kaiser, F, Doorduijn, J K, Salles, G, Szymczyk, M, Tilly, H, Kanz, L, Schmidt, C, Feugier, P, Thieblemont, C, Zijlstra, J M, Ribrag, V, Klapper, W, Pott, C, Unterhalt, M & Dreyling, M H 2020, ' Treatment of Older Patients With Mantle Cell Lymphoma (MCL) : Long-Term Follow-Up of the Randomized European MCL Elderly Trial ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, no. 3, pp. 248-256 . https://doi.org/10.1200/JCO.19.01294
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(3), 248-256. American Society of Clinical Oncology
PURPOSE In an update of the randomized, open-label, phase III European Mantle Cell Lymphoma (MCL) Elderly trial (ClinicalTrials.gov identifier: NCT00209209 ), published in 2012, we aimed to confirm results on long-term outcome focusing on efficacy an
Autor:
Ian Ganly, Fedaa Najdawi, Angela Chou, Antonio De Leo, Justine A. Barletta, Philip M. Spanheimer, Abir Al Ghuzlan, Alex Papachristos, Dana M. Hartl, Mohammed Alghamdi, Aradhya Nigam, Bayan Alzumaili, Christina Kanaan, Anthony J. Gill, James A. Fagin, Bin Xu, Eric Baudin, Erica Solaroli, Brian R. Untch, Sara Ahmadi, Andrea Repaci, Mohamed-Amine Bani, Anthony Glover, Ronald Ghossein, Giovanni Tallini, Talia L Fuchs, Pierre Khneisser
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(1)
PURPOSE Medullary thyroid carcinoma (MTC) is an aggressive neuroendocrine tumor (NET) arising from the calcitonin-producing C cells. Unlike other NETs, there is no widely accepted pathologic grading scheme. In 2020, two groups separately developed sl
Autor:
Massimo Aglietta, Tomislav Dragovich, Sara Lonardi, Michael J. Overman, Jean-Marie Ledeine, Usman Shah, Dana Backlund Cardin, Alain Hendlisz, Eric Van Cutsem, J. Gricar, María Luisa Limón, Sandzhar Abdullaev, Bart Neyns, Gabriele Luppi, Ka Yeung Mark Wong, Pilar García-Alfonso, Heinz-Josef Lenz
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(2)
PURPOSE Nivolumab received US Food and Drug Administration approval as a single agent or in combination with ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) that p
Autor:
Steven P. Treon, Jeffrey Matous, Meletios A. Dimopoulos, Ramón García-Sanz, Leonard T. Heffner, Jerry Ping, M. Lia Palomba, Veronique Leblond, Israel Arango-Hisijara, B. Hauns, Christian Buske, David MacDonald, Alessandra Tedeschi, Charles Herbaux, Chaim Shustik, Beatrice Mahe, Marzia Varettoni, Judith Trotman, Constantine S. Tam, Efstathios Kastritis
Publikováno v:
Journal of Clinical Oncology
Journal of Clinical Oncology, American Society of Clinical Oncology, 2021, ⟨10.1200/JCO.21.00838⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2021, ⟨10.1200/JCO.21.00838⟩
[Purpose]: The double-blind, randomized, placebo-controlled phase III iNNOVATE study showed sustained efficacy of ibrutinib-rituximab in Waldenström's macroglobulinemia (WM). Here, we present the final analysis from iNNOVATE. [Methods]: Patients had
Autor:
Suresh S. Ramalingam, Lei He, Mária Szilasi, Martin Dunbar, Bruce A. Bach, Ramaswamy Govindan, Julien Mazieres, Silvia Novello, R. Bernabé, Xin Huang, Everett E. Vokes, Peter Ansell, Salih Zeki Guclu, Dmitry Bentsion, Philip Clingan, Zanete Zvirbule, Jair Bar, Vasudha Sehgal, Konstantinos N. Syrigos, Jaimee Glasgow, Lauren Averett Byers
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(32)
PURPOSE Squamous non–small-cell lung cancer (sqNSCLC) is genetically complex with evidence of DNA damage. This phase III study investigated the efficacy and safety of poly (ADP-ribose) polymerase inhibitor veliparib in combination with conventional
Autor:
Annette Juul Vangsted, Abdullah A. Masud, Jeremy A. Ross, Simon J. Harrison, Shir-Jing Ho, Torben Plesner, Hang Quach, Nizar J. Bahlis, Rachid Baz, Orlando F. Bueno, Sheryl Coppola, Xiaoqing Yang, Simon D. J. Gibbs, Jonathan L. Kaufman, Philippe Moreau
Publikováno v:
Bahlis, N J, Baz, R, Harrison, S J, Quach, H, Ho, S J, Vangsted, A J, Plesner, T, Moreau, P, Gibbs, S D, Coppola, S, Yang, X, Al Masud, A, Ross, J A, Bueno, O & Kaufman, J L 2021, ' Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14) ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 39, no. 32, pp. 3602-3612 . https://doi.org/10.1200/JCO.21.00443
PURPOSE Venetoclax is an oral BCL-2 inhibitor with single-agent activity in patients with relapsed or refractory multiple myeloma (RRMM) with t(11;14) translocation. Venetoclax efficacy in RRMM may be potentiated through combination with agents inclu
Autor:
Wenfeng Fang, Zhixiong Lin, Chong Zhao, Quanlie Yang, Yan Huang, Jun Jia, Jiewen Peng, Shixiu Wu, Yaxiong Zhang, Mingjun Xu, Conghua Xie, Rensheng Wang, Jianji Pan, Xiaozhong Chen, Yunpeng Yang, Peijian Peng, Xiaolong Cao, Xuping Xi, Jianping Xiong, Qin Lin, Xuan Wu, Yingni Lian, Jin-Gao Li, Xiaojun Lu, Li Zhang, Zhihua Li, Qing Lin, Gengsheng Yu, Dongping Chen, Shaodong Hong
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(29)
PURPOSEGEM20110714 (ClinicalTrials.gov identifier: NCT01528618 ), the first randomized, phase III study of systemic chemotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC), reported significant progression-free survival improvement wit